MICHELLE TALKINGTON: Open Payments
NPI 1700225638 · SHERMAN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$428 in 25 payments from 8 companies in 2025. Trend: 2023 $89 · 2024 $55 · 2025 $428
Food & beverage: $428
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 7 | $138 |
| AstraZeneca Pharmaceuticals LP | 6 | $96 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $46 |
| Lilly USA, LLC | 3 | $46 |
| GlaxoSmithKline, LLC. | 2 | $41 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $32 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $11 |
Products named: Rybelsus, FARXIGA, Kerendia, Ozempic, TRELEGY ELLIPTA, JARDIANCE, MOUNJARO, BREZTRI.
Industry payments across TX — which companies pay providers there.
